Is it time to ban all antibiotics as animal growth-promoting agents?

Mudd, AJ

doi:10.1016/s0140-6736(04)70103-8

Cited by 7 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, a large body of experimental evidence and empirical data from the food industry has shown that Firmicute probiotics ( e.g. , Lactobacillus and Enterococcus ) and antibiotics that modify the gut microbiota can act as growth promoters, increasing the size and weight of animals [16] , [17] , [18] . Moreover, we recently found that Lactobacillus was significantly increased in the stools of obese patients [19] .…”

Section: Introductionmentioning

confidence: 99%

Vancomycin Treatment of Infective Endocarditis Is Linked with Recently Acquired Obesity

et al. 2010

View full text Add to dashboard Cite

BackgroundGut microbiota play a major role in digestion and energy conversion of nutrients. Antibiotics, such as avoparcin (a vancomycin analogue), and probiotics, such as Lactobacillus species, have been used to increase weight in farm animals. We tested the effect of antibiotics given for infective endocarditis (IE) on weight gain (WG).Methodology/Principal FindingsForty-eight adults with a definite diagnosis of bacterial IE (antibiotic group) were compared with forty-eight age-matched controls without IE. Their body mass index (BMI) was collected at one month before the first symptoms and one year after hospital discharge. The BMI increased significantly and strongly in vancomycin-plus-gentamycin–treated patients (mean [±SE] kg/m2, +2.3 [0.9], p = 0.03), but not in controls or in patients treated with other antibiotics. Seventeen patients had a BMI increase of ≥10%, and five of the antibiotic group developed obesity. The treatment by vancomycin-plus-gentamycin was an independent predictor of BMI increase of ≥10% (adjusted OR, 6.7; 95% CI, 1.37–33.0; p = 0.02), but not treatment with other antibiotics. Weight gain was particularly high in male patients older than 65 who did not undergo cardiac surgery. Indeed, all three vancomycin-treated patients with these characteristics developed obesity.Conclusions/SignificanceA major and significant weight gain can occur after a six-week intravenous treatment by vancomycin plus gentamycin for IE with a risk of obesity, especially in males older than 65 who have not undergone surgery. We speculate on the role of the gut colonization by Lactobacillus sp, a microorganism intrinsically resistant to vancomycin, used as a growth promoter in animals, and found at a high concentration in the feces of obese patients. Thus, nutritional programs and weight follow-up should be utilized in patients under such treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Vancomycin Treatment of Infective Endocarditis Is Linked with Recently Acquired Obesity

et al. 2010

View full text Add to dashboard Cite

show abstract

“…This was not the case in the USA, supporting the view that, in Europe, people were exposed to VRE from animal or environmental sources (Barton, 2000). This led to challenge on the use of avoparcin in animals (Mudd, 1996a, 1996b) then to a ban on its use in Europe in 1997. However, there was major controversy.…”

Section: Nontherapeutic Uses Of Antimicrobial Drugsmentioning

confidence: 99%

“…Many calls were made for a total ban on the use of all AMDs as growth promoters in animals (van den Bogaard & Stobberingh, 1996, 1999; Mudd, 1996b). In 1986, Sweden pioneered prohibition of incorporation of antibiotics in animal feeding‐stuffs, including the use of all antibiotic‐containing additives.…”

Section: Nontherapeutic Uses Of Antimicrobial Drugsmentioning

confidence: 99%

A history of antimicrobial drugs in animals: Evolution and revolution

Lees

Pelligand

Giraud

et al. 2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The evolutionary process of antimicrobial drug (AMD) uses in animals over a mere eight decades (1940–2020) has led to a revolutionary outcome, and both evolution and revolution are ongoing, with reports on a range of uses, misuses and abuses escalating logarithmically. As well as veterinary therapeutic perspectives (efficacy, safety, host toxicity, residues, selection of drug, determination of dose and measurement of outcome in treating animal diseases), there are also broader, nontherapeutic uses, some of which have been abandoned, whilst others hopefully will soon be discontinued, at least in more developed countries. Although AMD uses for treatment of animal diseases will continue, it must: (a) be sustainable within the One Health paradigm; and (b) devolve into more prudent, rationally based therapeutic uses. As this review on AMDs is published in a Journal of Pharmacology and Therapeutics, its scope has been made broader than most recent reviews in this field. Many reviews have focused on negative aspects of AMD actions and uses, especially on the question of antimicrobial resistance. This review recognizes these concerns but also emphasizes the many positive aspects deriving from the use of AMDs, including the major research‐based advances underlying both the prudent and rational use of AMDs. It is structured in seven sections: (1) Introduction; (2) Sulfonamide history; (3) Nontherapeutic and empirical uses of AMDs (roles of agronomists and veterinarians); (4) Rational uses of AMDs (roles of pharmacologists, clinicians, industry and regulatory controls); (5) Prudent use (residue monitoring, antimicrobial resistance); (6) International and inter‐disciplinary actions; and (7) Conclusions.

show abstract

“…In einer ersten Studie hemmte Imatinib das Tumorwachstum bei 32 von 36 Kranken mit einem metastasierenden gastrointestinalen Stromatumor. 8 Dabei handelt es sich um einen Sarkomtyp, der mit einer Mutation des Stammzellfaktor-Rezeptors assoziiert ist.…”

Section: Klinische Studienunclassified

Kein Glück mit Crevetten

Gysling¹

2001

View full text Add to dashboard Cite

show abstract

Is it time to ban all antibiotics as animal growth-promoting agents?

Cited by 7 publications

References 1 publication

Vancomycin Treatment of Infective Endocarditis Is Linked with Recently Acquired Obesity

Vancomycin Treatment of Infective Endocarditis Is Linked with Recently Acquired Obesity

A history of antimicrobial drugs in animals: Evolution and revolution

Kein Glück mit Crevetten

Contact Info

Product

Resources

About